We report here the results of a phase 3 study to assess the efficacy. safety. and tolerability of GC5107. a new 10% liquid intravenous immunoglobulin (IVIG) in preventing serious bacterial infections in patients with primary immunodeficiency (ClinicalTrials. https://ashleyshomestores.shop/product-category/4-piece-modular-sectional/